Vmn2r97 inhibitors pertain to a class of chemicals that specifically target the Vmn2r97 receptor, a member of a complex family of receptors known as vomeronasal type-2 receptors (V2Rs). These receptors are typically found in the vomeronasal organ (VNO), which is an olfactory structure involved in the detection of pheromones, chemical signals that can affect social and reproductive behaviors in animals. Vmn2r97 inhibitors are characterized by their ability to bind to this particular receptor subtype, thereby modulating its activity. The chemical nature of these inhibitors can vary widely, as they can be designed or discovered from a range of sources, including synthetic compounds, natural products, or as derivatives of existing molecules that have been structurally modified to increase their affinity and specificity towards the Vmn2r97 receptor.
The design and study of Vmn2r97 inhibitors require a deep understanding of the molecular architecture of the Vmn2r97 receptor itself. The receptor is a G protein-coupled receptor (GPCR), which is a large and diverse group of membrane receptors that respond to various extracellular substances. The interaction between a Vmn2r97 inhibitor and its target receptor involves the precise fit of the inhibitor into the receptor's binding site, which can block or modulate the receptor's ability to interact with its natural ligands. This blockade can alter the signal transduction pathways typically activated by the Vmn2r97 receptor. Researchers who focus on these inhibitors are interested in the specific conformational changes that occur upon inhibitor binding, how these changes affect signal transduction within the cell, and the subsequent biochemical cascade that is either initiated or inhibited as a result of this interaction. Understanding these interactions at a molecular level is crucial for the advancement of knowledge in fields like biochemistry and molecular biology, which in turn has implications for a broad range of scientific inquiries.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that could impede the activity of Vmn2r97 if it were part of a signaling cascade initiated by EGFR. By blocking EGFR, downstream signaling responsible for the functional activity of Vmn2r97 could be indirectly inhibited. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor affecting a broad range of kinases. If Vmn2r97's activity is dependent on a specific kinase signaling pathway, staurosporine could diminish its activity by inhibiting the necessary kinase. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that could potentially interfere with the MAPK/ERK pathway. If Vmn2r97 is regulated by this pathway, its activity would be indirectly decreased through the inhibition of MEK. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could disrupt PI3K/AKT signaling. If Vmn2r97 is downstream of PI3K/AKT signaling, its activity would be inhibited as a result of the inhibition of this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a central regulator of cell growth and proliferation. If Vmn2r97 is involved in these cellular processes through mTOR signaling, its activity would be diminished by rapamycin. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, and if Vmn2r97 functions downstream of p38 MAPK signaling, then its activity would be indirectly inhibited by preventing p38 MAPK activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which could lead to the inhibition of Vmn2r97 if it operates downstream of JNK signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. Similar to LY294002, if Vmn2r97 is regulated by PI3K signaling, its activity would be indirectly inhibited by wortmannin. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which operates upstream of ERK in the MAPK pathway. This could result in decreased activity of Vmn2r97 if it is regulated by or associated with the MAPK pathway. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide inhibits dihydroorotate dehydrogenase and can lead to decreased pyrimidine synthesis. If the function of Vmn2r97 is tied to the availability of pyrimidine bases, its activity could be indirectly inhibited by leflunomide. | ||||||